Semaglutides: weighing up the risks
-
Podcast martes, 22 de abril de 2025 martes, 22 de abril de 2025
-
North America, UK & Europe
-
Regulatory movement
-
Insurance
The first episode of our 2025 podcast series covers Semaglutides, a diabetes control drug that works by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite.
Partner Neil Beresford is joined by:
- Rosehana Amin, Partner, London
- Kirsten Soto, Senior Associate, Los Angeles
- Richard Manstoff, Senior Associate, London
Together they explore the potential risks and lawsuits surrounding Semaglutides, including their side effects and possible implications for insurers.
End
